Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2020-07-27 Major Shareholding Noti…
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Verona Pharma plc: TR-1: Standard form for notification of major holdings
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'NOTIFICATION OF MAJOR HOLDINGS' and contains structured fields typical of regulatory filings concerning changes in share ownership thresholds. Key sections include 'Details of person subject to the notification obligation', 'Date on which the threshold was crossed or reached', and tables detailing 'Voting rights attached to shares'. This structure strongly indicates a filing related to significant shareholder changes, which corresponds to the Major Shareholding Notification category (MRQ). The document is a direct notification, not an announcement of a report (RPA) or a general regulatory filing (RNS).
2020-07-27 English
Share option exercise and issue of equity
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated July 24, 2020. The content announces the exercise of share options and the subsequent issuance of new ordinary shares, leading to a change in the total number of voting rights. This type of announcement, which details changes in share capital or insider transactions and is distributed via the Regulatory News Service (RNS) of the London Stock Exchange, fits best under the general regulatory announcement category. While it relates to share capital changes (SHA) or director dealings (DIRS), the primary function here is a mandatory regulatory disclosure via RNS regarding an administrative change affecting the total share count. Given the explicit mention of 'RNS Number' and the nature of the announcement (share option exercise leading to new shares and total voting rights), the most appropriate classification is the general regulatory filing category, RNS, as it is a standard market notice.
2020-07-24 English
Closing of Financing, Issued Share Capital and Total Voting Rights
Capital/Financing Update Classification · 1% confidence The document is an update regarding a previously announced financing event ('$200 million Financing announced on July 17, 2020'). It details the 'Closing' of this financing, the resulting changes in the issued share capital, total voting rights, and updates on insider (PDMR) dealings related to the transaction. This content directly relates to capital structure changes, fundraising activities, and subsequent regulatory disclosures about share counts and insider transactions. The most fitting category is 'Capital/Financing Update' (CAP), as the primary focus is the completion and immediate consequences of raising capital. While it touches upon insider dealings (DIRS) and share structure (SHA), the overarching theme is the closing of the financing round.
2020-07-22 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1354 characters) and begins with 'RNS Number : 6335T', indicating it is a regulatory news service announcement from the London Stock Exchange. The content discusses a 'Price Monitoring Extension' for a security, which is a procedural update related to trading mechanisms, not a core financial report (like 10-K, ER, or IR). Since it is a general regulatory announcement that doesn't fit the specific categories like DIRS, DIV, or MANG, the most appropriate classification is the general regulatory filing fallback category.
2020-07-21 English
Verona Pharma plc: PDMR Dealings
Director's Dealing Classification · 1% confidence The document explicitly details transactions (purchases) of Ordinary Shares and ADSs by Persons Discharging Managerial Responsibilities (PDMRs) such as the Non-Executive Chairman, CEO, CFO, and Non-Executive Directors. This type of filing, which reports personal share transactions by company directors and executives, directly corresponds to the definition of 'Director's Dealing'. The presence of detailed tables listing names, positions, transaction types ('Purchase of Ordinary Shares', 'Subscription to purchase ADSs'), dates, and volumes confirms this classification. The relevant code is DIRS.
2020-07-17 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled with 'RNS Number : 3770T' and contains a standardized form titled 'TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES'. This form details changes in voting rights and share ownership thresholds (e.g., crossing the 1% threshold) by a specific shareholder (Enterprise Ventures Limited). This type of mandatory disclosure regarding significant changes in shareholding is classified as a Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2020-07-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.